title: [Therapeutic use of splenopentin (DA SP-5) in patients with psoriasis arthropathica].
abstract: 8 patients with confirmed psoriatic arthritis were treated with splenopentin for 12 months. A relief of joint pain could be detected under this treatment both after 6 weeks (improvement of the Ritchie-indices: 44%) and after 12 months (improvement: 28%). In contrast to this, X-ray investigations show a worsening of the disease after 12 months. Therefore we conclude that splenopentin alone is not a sufficient therapeutic drug in patients suffering from psoriatic arthritis.
authors.affiliation: Klinik und Poliklinik für Hautkrankheiten, Humboldt-Universität zu Berlin, DDR.
authors.forename: J
authors.initials: J
authors.lastname: Greiner
authors.forename: M
authors.initials: M
authors.lastname: Miehe
authors.forename: H
authors.initials: H
authors.lastname: Weber
authors.forename: A
authors.initials: A
authors.lastname: Stoimenov
authors.forename: N
authors.initials: N
authors.lastname: Sönnichsen
authors.forename: W
authors.initials: W
authors.lastname: Diezel
mesh_terms: D000328:Adult; D015535:Arthritis, Psoriatic / Q000628:therapy*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000008:administration & dosage*; D013946:Thymopoietins / Q000008:administration & dosage*; D013951:Thymus Hormones / Q000008:administration & dosage*
chemical_list: D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; C060485:berlopentin
vernacular_title: Therapeutische Anwendung von Splenopentin (DA SP-5) bei Patienten mit Psoriasis arthropathica.